NL-OMON52141招募中4 期
Efficacy, safety and cost-effectiveness of B cell tailored ocrelizumab versus standard ocrelizumab in relapsing remitting multiple sclerosis: a randomized controlled trial - BLOOMS trial
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 入组人数
- 296
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •multiple sclerosis
- •minimally 48 weeks of treatment with ocrelizumab
排除标准
- •age below 18
- •inability to undergo frequent MRIs
研究者
相似试验
进行中（未招募）
1 期
Personalized dosing of ocrelizumab in MSMultiple sclerosisEUCTR2021-004791-34-NLVU medical center296
进行中（未招募）
4 期
B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingNCT05296161Amsterdam UMC, location VUmc296
尚未招募
不适用
Effectiveness and safety of low dose Rituximab in primary membranous nephropathyCTRI/2020/12/029849il
进行中（未招募）
不适用
Evaluation of the immune response and safety of a booster dose of Pfizer's13-valent pneumococcal conjugate vaccine in children primed with 2 dosesof either GSK's 10-valent pneumococcal conjugate vaccine or Pfizer's 13-valent pneumococcal conjugate vaccine in the Slovak RepublicTo induce appropriate protection against pneumococcal disease. Toassess non-inferiority of OPA response for serotype 19A after boosterdose of PCV13 administered between 11-12 months of age in subjectsprimed with 10Pn-PD-DiT vs those primed with PCV13.EUCTR2012-005367-27-SKBIOVOMED
进行中（未招募）
不适用
Evaluation of the immune response and safety of a booster dose of Pfizer’s 13-valent pneumococcal conjugate vaccine in children primed with 3 doses of either GSK’s 10-valent pneumococcal conjugate vaccine or Pfizer’s 13-valent pneumococcal conjugate vaccine in the Czech Republic.To induce appropriate protection against pneumococcal disease. To assess non-inferiority of OPA response for serotype 19A after booster dose of PCV13 administered between 12-15 months of age in subjects primed with 10Pn-PD-DiT vs those primed with PCV13.EUCTR2012-005366-35-CZBIOVOMED